Edding Group Co. Ltd. announced June 23 it filed for an IPO on the Hong Kong Exchange – news that comes amid a steep drop in China’s biopharma IPO market forecasting sluggish activity in a near-frozen “capital winter.”
Researchers at NYU Langone Health and Janssen Biotech Inc. have reported on mAbtyrins, bioengineered molecules composed of human monoclonal antibodies and centyrins that are a new way to fight Staphylococcus aureus infection on all fronts.In their experiments, which were published in Cell Host & Microbe on April 24, 2023, the team described mAbtyrin, as “a protein-based therapeutic that targets 10 disease-causing mechanisms employed by S. aureus,” senior author Victor Torres told BioWorld.
Researchers from the University of Queensland have published preclinical data on the novel glycopeptide antibiotic MCC-5145, being developed for the treatment of gram-positive bacterial infections.
The data safety monitoring board overseeing Contrafect Corp.’s phase III study of exebacase, a hydrolase stimulator for treating Staphylococcus aureus bacteremia, recommended the study be stopped. In an interim analysis, the board said the conditional power of the study was below the prespecified threshold for futility.
The accepted wisdom that resistance to antibiotics is a modern phenomenon driven by their overuse is called into question by new research showing the genes that give methicillin-resistant Staphylococcusaureus (MRSA) its superbug status existed in nature long before antibiotics were first deployed in the clinic.
Developing the next generation of antibiotics is proving to be a major problem, with research reaching an almost standstill due to a lack of funding because of the poor return on R&D investment from the products.
